Reunion Neuroscience EBIT

Reunion Neuroscience (REUN) currently reports a EBIT of $-19M as of March 2023. That compares with $-53M in the prior-year period — up 64.3% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Reunion Neuroscience's EBIT history and peer comparisons.

Reunion Neuroscience's EBIT increased from $-53M to $-19M — a 64.3% year-over-year increase (period ending March 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Reunion Neuroscience's EBIT of $-19M is lower than the Healthcare sector average of $23B. That is roughly 100.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Reunion Neuroscience reported $-19M in EBIT as of March 2023. That compares with $-53M in the prior-year period — up 64.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-19M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Reunion Neuroscience, and consider following REUN for alerts when major investors trade the stock.